Lynnor Stevenson, PhD, has 30 yrs experience bioscience startups. CEO of 4 bio companies including Heska (HSKA), and member of 10 founding teams for companies, 6 of which had successful exits by IPO. She was the founding CEO and a long time member of the Board of Directors of Heska Corporation, a public animal health company that develops drugs, vaccines and diagnostics.

Sandra Shotwell, PhD, has 20 yrs experience in technology commercialization and startups, including 3 yrs as Head of Licensing, NIH. Experience includes negotiating license and research partnerships with large pharmaceutical companies, and founding and serving as a board member for start-up companies. She also is a nationally-recognized authority on the role of intellectual property in the development of drugs for neglected diseases.

David Peyton, PhD., is co-inventor of DM technology. He has been working on medicinal chemistry of malaria for more than a decade and brings over two decades of organic, physical, and analytical chemistry experience. He is a Professor of Chemistry at Portland State University.

James Wilson, M.S. is a senior executive with more than 20 years experience in providing clinical trial services to the biopharmaceutical industries. He joined Clinimetrics in 1989 and served as co-principal, growing the company entirely through retained earnings to more than 350 world-wide employees prior to being acquired by fortune 500
company, Omnicare. He is an active angel investor.

Erik Iverson is EVP, Business Development at the Infectious Disease Research Institute (IDRI) Seattle, Wa, a global health research institute developing diagnostics, vaccines, and treatments for neglected diseases of poverty. Prior to joining IDRI, he was Associate General Counsel at the Bill & Melinda Gates Foundation where he led development and implementation of the Foundation’s Global Access policy through grants and strategic initiatives.